Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00064467
Status:
COMPLETED
Last Update Posted:
2017-05-30
First Post:
2003-07-08
Brief Title:
Lethargic Depression Study
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An 8 Week Multicenter Randomized Double-blind Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of Major Depressive Disorder MDD in patients with decreased energy pleasure and interests
Detailed Description:
A Multicenter Double-Blind Placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion HCl 300-450 mgday and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy pleasure and interest
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None